{"id":24168,"date":"2026-03-03T17:53:09","date_gmt":"2026-03-03T17:53:09","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/24168\/"},"modified":"2026-03-03T17:53:09","modified_gmt":"2026-03-03T17:53:09","slug":"qyuns-and-roche-partner-in-1b-bispecific-antibody-deal-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/24168\/","title":{"rendered":"Qyuns and Roche partner in $1B+ bispecific antibody deal"},"content":{"rendered":"<p>To read the full story, <a href=\"https:\/\/www.bioworld.com\/subscriptions\" rel=\"nofollow noopener\" target=\"_blank\">subscribe<\/a> or <a href=\"https:\/\/www.bioworld.com\/user\/login\" rel=\"nofollow noopener\" target=\"_blank\">sign in<\/a>.<\/p>\n<p>Oct. 29, 2025<\/p>\n<p>  By <a href=\"https:\/\/www.bioworld.com\/authors\/603-marian-yoonjee-chu\" rel=\"nofollow noopener\" target=\"_blank\">Marian (YoonJee) Chu<\/a><\/p>\n<p>  <a title=\"Qyuns and Roche partner in $1B+ bispecific antibody deal\" class=\"more\" href=\"https:\/\/www.bioworld.com\/articles\/725590-qyuns-and-roche-partner-in-1b-bispecific-antibody-deal#comments-container\" rel=\"nofollow noopener\" target=\"_blank\">No Comments<\/a><\/p>\n<p>Qyuns Therapeutics Co. Ltd. signed a potential $1.07 billion license deal with Roche Holding AG, granting the latter exclusive rights to QX-031N \u2013 a human thymic stromal lymphopoietin and interleukin-33)-targeting bispecific antibody.<\/p>\n<p><a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/84-bioworld\" rel=\"nofollow noopener\" target=\"_blank\">BioWorld<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/214-deals-and-m-a\" rel=\"nofollow noopener\" target=\"_blank\">Deals and M&amp;A<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/250-immune\" rel=\"nofollow noopener\" target=\"_blank\">Immune<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/263-respiratory\" rel=\"nofollow noopener\" target=\"_blank\">Respiratory<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/273-bispecific-antibody\" rel=\"nofollow noopener\" target=\"_blank\">Bispecific antibody<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/393-asia-pacific\" rel=\"nofollow noopener\" target=\"_blank\">Asia-Pacific<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/396-europe\" rel=\"nofollow noopener\" target=\"_blank\">Europe<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/442-ind\" rel=\"nofollow noopener\" target=\"_blank\">IND<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/556-nmpa\" rel=\"nofollow noopener\" target=\"_blank\">NMPA<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"To read the full story, subscribe or sign in. Oct. 29, 2025 By Marian (YoonJee) Chu No Comments&hellip;\n","protected":false},"author":2,"featured_media":24144,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[941,3780,8086,2993,8568,15280,197,14713,15284,15286,15285,15281,15278,15277,14716,134,473,15283,15279,15282],"class_list":{"0":"post-24168","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-asia-pacific","9":"tag-astegolimab","10":"tag-bioworld","11":"tag-bispecific-antibody","12":"tag-deals-and-ma","13":"tag-dupixent","14":"tag-europe","15":"tag-il-33","16":"tag-immune","17":"tag-ind","18":"tag-nmpa","19":"tag-qx-001s","20":"tag-qx-031n","21":"tag-qyuns-therapeutics-co-ltd","22":"tag-respiratory","23":"tag-roche","24":"tag-roche-holding-ag","25":"tag-sailexin","26":"tag-tslp","27":"tag-ustekinumab-biosimilar"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116166525578866113","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/24168","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=24168"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/24168\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/24144"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=24168"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=24168"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=24168"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}